Cargando…
Prise en charge des tumeurs primitives et métastatiques du péritoine en période de pandémie CoViD-19. Pistes de réflexion et de priorisation du groupe RENAPE et BIG-RENAPE()
The Covid-19 pandemic is profoundly changing the organization of healthcare access. This is particularly so for peritoneal neoplastic diseases, for which curative treatment mobilizes substantial personnel, operating room and intensive care resources. The BIG-RENAPE and RENAPE groups have made tentat...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Masson SAS.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177067/ https://www.ncbi.nlm.nih.gov/pubmed/32328206 http://dx.doi.org/10.1016/j.jchirv.2020.04.011 |
_version_ | 1783525138309840896 |
---|---|
author | Glehen, O. Kepenekian, V. Bouché, O. Gladieff, L. Honore, C. |
author_facet | Glehen, O. Kepenekian, V. Bouché, O. Gladieff, L. Honore, C. |
author_sort | Glehen, O. |
collection | PubMed |
description | The Covid-19 pandemic is profoundly changing the organization of healthcare access. This is particularly so for peritoneal neoplastic diseases, for which curative treatment mobilizes substantial personnel, operating room and intensive care resources. The BIG-RENAPE and RENAPE groups have made tentative proposals for prioritizing care provision. A tightening of the usual selection criteria is needed for curative care: young patients with few or no comorbidities and limited peritoneal extension. It is desirable to prioritize disease conditions for which cytoreduction surgery with or without associated hyperthermic intraoperative peritoneal chemotherapy (HIPEC) is the gold-standard treatment, and for which systemic chemotherapy cannot be a temporary or long-term alternative: pseudomyxoma peritonei, resectable malignant peritoneal mesotheliomas, peritoneal metastases of colorectal origin if they are resectable and unresponsive to systemic chemotherapy after up to 12 courses, first-line ovarian carcinomatosis if resectable or in interval surgery after at most six courses of systemic chemotherapy. Addition of HIPEC must be discussed case by case in an expert center. The prioritization of indications must consider local conditions and the phase of the epidemic to allow optimal peri-operative care. |
format | Online Article Text |
id | pubmed-7177067 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Published by Elsevier Masson SAS. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71770672020-04-23 Prise en charge des tumeurs primitives et métastatiques du péritoine en période de pandémie CoViD-19. Pistes de réflexion et de priorisation du groupe RENAPE et BIG-RENAPE() Glehen, O. Kepenekian, V. Bouché, O. Gladieff, L. Honore, C. J Chir Visc Article The Covid-19 pandemic is profoundly changing the organization of healthcare access. This is particularly so for peritoneal neoplastic diseases, for which curative treatment mobilizes substantial personnel, operating room and intensive care resources. The BIG-RENAPE and RENAPE groups have made tentative proposals for prioritizing care provision. A tightening of the usual selection criteria is needed for curative care: young patients with few or no comorbidities and limited peritoneal extension. It is desirable to prioritize disease conditions for which cytoreduction surgery with or without associated hyperthermic intraoperative peritoneal chemotherapy (HIPEC) is the gold-standard treatment, and for which systemic chemotherapy cannot be a temporary or long-term alternative: pseudomyxoma peritonei, resectable malignant peritoneal mesotheliomas, peritoneal metastases of colorectal origin if they are resectable and unresponsive to systemic chemotherapy after up to 12 courses, first-line ovarian carcinomatosis if resectable or in interval surgery after at most six courses of systemic chemotherapy. Addition of HIPEC must be discussed case by case in an expert center. The prioritization of indications must consider local conditions and the phase of the epidemic to allow optimal peri-operative care. Published by Elsevier Masson SAS. 2020-06 2020-04-23 /pmc/articles/PMC7177067/ /pubmed/32328206 http://dx.doi.org/10.1016/j.jchirv.2020.04.011 Text en © 2020 Published by Elsevier Masson SAS. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Glehen, O. Kepenekian, V. Bouché, O. Gladieff, L. Honore, C. Prise en charge des tumeurs primitives et métastatiques du péritoine en période de pandémie CoViD-19. Pistes de réflexion et de priorisation du groupe RENAPE et BIG-RENAPE() |
title | Prise en charge des tumeurs primitives et métastatiques du péritoine en période de pandémie CoViD-19. Pistes de réflexion et de priorisation du groupe RENAPE et BIG-RENAPE() |
title_full | Prise en charge des tumeurs primitives et métastatiques du péritoine en période de pandémie CoViD-19. Pistes de réflexion et de priorisation du groupe RENAPE et BIG-RENAPE() |
title_fullStr | Prise en charge des tumeurs primitives et métastatiques du péritoine en période de pandémie CoViD-19. Pistes de réflexion et de priorisation du groupe RENAPE et BIG-RENAPE() |
title_full_unstemmed | Prise en charge des tumeurs primitives et métastatiques du péritoine en période de pandémie CoViD-19. Pistes de réflexion et de priorisation du groupe RENAPE et BIG-RENAPE() |
title_short | Prise en charge des tumeurs primitives et métastatiques du péritoine en période de pandémie CoViD-19. Pistes de réflexion et de priorisation du groupe RENAPE et BIG-RENAPE() |
title_sort | prise en charge des tumeurs primitives et métastatiques du péritoine en période de pandémie covid-19. pistes de réflexion et de priorisation du groupe renape et big-renape() |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177067/ https://www.ncbi.nlm.nih.gov/pubmed/32328206 http://dx.doi.org/10.1016/j.jchirv.2020.04.011 |
work_keys_str_mv | AT gleheno priseenchargedestumeursprimitivesetmetastatiquesduperitoineenperiodedepandemiecovid19pistesdereflexionetdepriorisationdugrouperenapeetbigrenape AT kepenekianv priseenchargedestumeursprimitivesetmetastatiquesduperitoineenperiodedepandemiecovid19pistesdereflexionetdepriorisationdugrouperenapeetbigrenape AT boucheo priseenchargedestumeursprimitivesetmetastatiquesduperitoineenperiodedepandemiecovid19pistesdereflexionetdepriorisationdugrouperenapeetbigrenape AT gladieffl priseenchargedestumeursprimitivesetmetastatiquesduperitoineenperiodedepandemiecovid19pistesdereflexionetdepriorisationdugrouperenapeetbigrenape AT honorec priseenchargedestumeursprimitivesetmetastatiquesduperitoineenperiodedepandemiecovid19pistesdereflexionetdepriorisationdugrouperenapeetbigrenape AT priseenchargedestumeursprimitivesetmetastatiquesduperitoineenperiodedepandemiecovid19pistesdereflexionetdepriorisationdugrouperenapeetbigrenape |